Health
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program
SEATTLE, April 10, 2025--Omeros Corporation (Nasdaq: OMER) today announced the establishment of the Omeros Oncology Clinical Steering Committee to advance Omeros’ OncotoX biologics program focused on acute myeloid leukemia (AML). AML is the most fatal form of leukemia and accounts for approximately 80 percent of acute leukemias in adults and one-third of all cancers affecting the blood/bone marrow, representing a high unmet need. Omeros’ OncotoX program for AML consists of proprietary targeted,
About this update from Omeros Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":342,"url":"https://media.zenfs.com/en/business-wire.com/67534bb8a26201127b9e398c12537bad"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_umQpLKLf9jy3JhDQXZmeg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY4NDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/67534bb8a26201127b9e398c12537bad","width":480,"height":342}},"lazy":false},{"type":"text","content":"– The Steering Committee brings together distinguished clinical experts in AML from leading National Comprehensive Cancer Network Centers –","length":139,"tagName":"p","attribs":{}},{"type":"text","content":"SEATTLE, April 10, 2025--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the establishment of the Omeros Oncology Clinical Steering Committee to advance Omeros’ OncotoX biologics program focused on acute myeloid leukemia (AML). AML is the most fatal form of leukemia and accounts for approximately 80 percent of acute leukemias in adults and one-third of all cancers affecting the blood/bone marrow, representing a high unmet need. Omeros’ OncotoX program for AML consists of proprietary targeted, engineered molecules (about half the size of an antibody) that deliver a toxic payload within the cancer cells, thereby killing them.","length":650,"tagName":"p"},{"type":"text","content":"Members of the Omeros Oncology Clinical Steering Committee include:","length":67,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Naval Daver, M.D., Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center (Chair of the Omeros Oncology Clinical Steering Committee)","length":201,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Aref Al-Kali, M.D., Chair of the Acute Myeloid Group and Research Chair of the Acute Leukemia and Myeloid Neoplasms Disease Group at Mayo Clinic","length":144,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Jessica K. Altman, M.D., Professor of Medicine in the Division of Hematology and Oncology and Director of the Leukemia Program of Robert H. Lurie Comprehensive Cancer Center at Northwestern University","length":200,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Jayastu Senapa...